RESUMEN
PURPOSE: To comprove the efficiency of acetyl salicylic acid (ASA) as platelet antiaggregant drug, a 100 mg/day dose base. METHODS: Two hundred and fifty-eight patients were studied between 1988 and 1990. Platelet functions were measured using an aggregometer plus ADP 5 as platelet aggregation inductor. RESULTS: Two groups were studied: 1st group, using ASA (111 patients), 91 hypoaggregants; 2nd group, not using ASA (147 patients), 120 normals, 12 hypoaggregants and 15 hyperaggregants. From the 2nd group, 91 had another evaluation under the use of ASA and showed a clear effect of the drug. CONCLUSION: The use of aspirin, 100 mg/day dose, is enough to reduce platelet antiaggregation.
Asunto(s)
Aspirina/administración & dosificación , Adolescente , Adulto , Anciano , Niño , Evaluación de Medicamentos , Cardiopatías/sangre , Cardiopatías/tratamiento farmacológico , Hemostasis/efectos de los fármacos , Humanos , Hipertensión/sangre , Hipertensión/tratamiento farmacológico , Persona de Mediana Edad , Agregación Plaquetaria/efectos de los fármacosRESUMEN
A sindrome de Holt-Oram e entidade rara e caracteriza-se por malformacoes esqueleticas e cardiopatias congenitas. E determinada por gene autossomico dominante. E apresentado um caso em que o defeito cardiaco associado era a persistencia do canal AV comum, forma total, achado nunca antes comprovado. Sao revistos e discutidos os aspectos clinicos e geneticos